Low testosterone reduces sexual desire and musculoskeletal function in postmenopausal women.

The decline of androgen levels following menopause is increasingly recognized as a significant factor in female physiological aging, impacting both neurobiological and structural systems.

Clinical evidence for sexual and musculoskeletal health

Extensive research supports a strong correlation between low testosterone and diminished health outcomes in postmenopausal women. Regarding sexual function, meta-analyses of randomized controlled trials (RCTs) demonstrate that restoring testosterone to physiological premenopausal ranges significantly improves Hypoactive Sexual Desire Disorder (HSDD). These interventions consistently yield a mean increase of approximately 0.85 satisfying sexual events (SSEs) per month (p < 0.001) and improved scores for arousal and orgasm.

In the musculoskeletal domain, low testosterone is a primary contributor to the "musculoskeletal syndrome of menopause" (MSM), which manifests as myalgia, arthralgia, and reduced physical strength. Longitudinal data from the Study of Women's Health Across the Nation (SWAN) show that higher bioavailable testosterone is associated with higher bone mineral density (BMD) and a slower rate of bone loss. Conversely, serum levels below 20–30 ng/dL are linked to an increased risk of osteopenia and sarcopenia.

Mechanistic explanations

These clinical observations are underpinned by specific androgen receptor (AR) mediated pathways:

• Central Nervous System: Testosterone crosses the blood-brain barrier to bind ARs in the mesocorticolimbic system. This activation modulates dopamine signaling, which is essential for reward processing, sexual motivation, and responsiveness to stimuli.
• Muscle Protein Synthesis: In muscle tissue, testosterone activates the AKT-mTOR signaling pathway. This stimulates fractional protein synthesis rates—shown to increase by approximately 50% following administration—and promotes satellite cell proliferation necessary for maintaining lean mass.
• Bone Homeostasis: Testosterone acts directly on ARs located on osteoblasts to promote bone formation. It also works synergistically with estrogen to inhibit bone resorption, maintaining the structural integrity of the skeletal matrix.

Bottom line

• The association between low testosterone and reduced sexual desire and musculoskeletal function is robustly supported; physiological restoration can significantly improve libido, muscle protein synthesis, and bone density in postmenopausal women.